Bajaj Healthcare Q1 FY27 Earnings Call — Analysis (NSE: BAJAJHCARE)

Bajaj Healthcare guides 10-15% FY27 revenue growth, targets margin expansion through peptide and oncology capacity build

27 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue ₹165.6 Cr ( +11.3% YoY ) . New guidance — FY27 fy27 revenue growth 10-15% . New story: Product mix shift to high-value APIs .

Results

Revenue ₹165.6 Cr +11.3% YoY; EBITDA margin 17.8% (+70bps); PAT ₹13.9 Cr +14.1% YoY; domestic API volume-led growth 27%

Financial highlights

Guidance

FY27 revenue growth 10-15%, EBITDA margin 18-20%, exports to reach 30-35% of mix, and annual capex ₹40-50 Cr

What management committed to

• Bajaj Healthcare expects FY27 revenue growth of 10-15% year-on-year — 10-15%, FY27
• [FY27 profit growth] will be similar to revenue growth (10-15% YoY) — similar to revenue growth (10-15%), FY27
• [Bajaj Healthcare's] EBITDA margin will be 18-20% in FY27 and FY28 — 18-20%, FY28
• [Bajaj Healthcare's] export revenue share will rise to 30-35% in the near future — 30-35%, near future
• [Bajaj Healthcare's peptide facility] at peak full utilisation can generate ₹200-300 Cr revenue — ₹200-300 Cr
• [Bajaj Healthcare's peptide facility] will deliver EBITDA margin of 18-20% — 18-20%
• [Cenobamate tablets] will generate ₹10-12 Cr revenue in FY27 — ₹10-12 Cr, FY27
• [Magnesium L-Threonate] export revenue will grow 15-20% in FY27 — 15-20%, FY27
• [Bajaj Healthcare] will launch at least two brands of Magnesium L-Threonate CDMO in India in Q3 FY27 — at least two brands, Q3FY27
• [GenRx facility] will commence commercial production in H2 FY27 — H2 FY27, FY27
• [Dedicated peptide manufacturing facility] will be commissioned in Q4 FY27 — Q4 FY27, Q4FY27
• [Oncology API dedicated facility] will be commercialised in Q4 FY28 — Q4 FY28, Q4FY28

Key themes

High-value API capex and first-mover regulatory milestones

How the narrative shifted

• Product mix shift to high-value APIs: Management is consciously shifting the mix from bulk APIs to high-margin branded, peptide, oncology, and CNS specialty products, leveraging first-mover regulatory milestones.
• Capex cycle for future growth: Significant capacity expansion underway – peptide, oncology, GenRx, R&D – with annual capex of ₹40-50 Cr to capture next wave of high-value molecules.
• Regulatory milestones unlocking revenue: First-in-India SEC recommendation for Cenobamate, CEP approvals in EU, and upcoming Suvorexant approvals position the company as a reliable partner for CDMO and branded CNS formulations.
• Domestic API volume-led growth: Domestic API business grew 27% on stable pricing and volume gains, demonstrating resilience despite geopolitical volatility and China dependency concerns.
• Export mix expansion ambition: Export share targeted to double to 30-35% as EU registrations, nutraceutical licensing, and easing geopolitical conditions convert into revenue.
• Balance sheet strengthening and working capital discipline: Debt-to-equity reduced to 0.45, operating cash flow improved, and management targets 110-120 receivable days; CFO highlights ROE/ROA as key 3-year metrics.
• Nutraceutical licensing as new growth avenue: Exclusive license for Magnesium L-Threonate (Magtein) opens a differentiated nutraceutical stream with export to US innovator and upcoming CDMO launches in India.
• Backward integration to reduce import dependency: Backward integration across 8-10 molecules and Vitamin C fermentation via ICT aims to improve margins by 1-2% and reduce China dependence, with long gestation.

Operational commentary

• Peptide facility: 250 kg/yr dedicated plant commissioning Q4 FY27, first product Semaglutide; peak revenue potential ₹200–300 Cr at 18–20% EBITDA margin
• Oncology API: dedicated facility targeted for Q4 FY28; company expects margin uplift from shift to high-value molecules
• Cenobamate Tablets: first company in India to secure SEC recommendation; awaiting DCGI NOC; CDMO tie-up with eight marketing partners, FY27 revenue guidance ₹10–12 Cr
• Bajaj Oncocare: launched 2024, now present in 23 states/3 UTs with 15+ brands; first to launch Posaconazole 300 mg tablet; B2C oncology platform scaling
• Magnesium L-Threonate (Magtein): exclusive license from innovator, exporting to US patent holder; CDMO launch in India with at least two brands targeted Q3 FY27; 350 MT exported in FY26, 15–20% growth guided for FY27
• R&D expansion: new 10,000 sq ft facility at Savli operational Aug 2026; >100 scientists; R&D spend rose from 0.4% of sales in FY24 to 2.2% in FY26
• GenRx acquisition (Nashik) under NCLT: solid dosage facility, commercial production expected H2 FY27
• EU/UK API registrations: received six CEP approvals in 6–8 months; commercialization expected FY28-end, with volume commitment but pricing to be determined
• Backward integration: 8–10 molecules being backward integrated to reduce China dependency, margin improvement 1–2%; Vitamin C fermentation technology with ICT targeted completion 2029
• API pricing stable QoQ; domestic API volume growth 27% driven by volume, not price; opium derivative R&D ongoing with two molecules; government discussions for increased capacity
• Divestment of Tarapur loss-making units: one sold, two remaining; proceeds from remaining units yet to be negotiated

Analyst Q&A

• Q. API price trends and outlook

  Stable this quarter; future depends on geopolitical situation and oil prices

• Q. Revenue and profitability guidance for FY27

  Revenue growth 10–15%, similar growth rate for profits

• Q. Commercial opportunity of Cenobamate tablets

  Tied up with eight CDMO partners; launching quantity ₹10–12 Cr in FY27

• Q. Peptide plant commercial revenue timeline

  Commercialization Q4 FY27, revenue in FY28; customer qualifications after plant start

• Q. CDMO progress in UK/EU – quantum of business

  Volume commitment is good, but pricing will depend on molecule prices after 1–1.5 years; unable to quantify now

• Q. Suvorexant market size

  Will send details offline

• Q. Long-term revenue target 3 years out

  ₹900–1,000 Cr possible in 2–3 years

View source

Research and educational content only. Not investment advice.